腾药Tengyao品牌怎么样 申请店铺

更新时间:2023-03-31
腾药Tengyao是哪个国家的品牌?「腾药Tengyao」是 云南腾药制药股份有限公司 旗下著名品牌。该品牌发源于云南省保山市,由创始人赵丙贤在1990-06-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
腾药Tengyao怎么样

云南腾药制药股份有限公司(以下简称“腾药”)成立于1956年,1997年改为股份合作制企业,2011年9月在县委政府的关心支持下完成股份制改造,同年11月与北京中证万融医药投资集团实现战略合作。

历经五十多年历史积淀的腾药,目前在编在岗员工600余人(含销售人员),具备了雄厚的制药技术基础,公司在不断汲取现代科学技术的基础上具备了专业的检测手段。两者的有机结合,使“腾药”产品有了过硬的质量,造就的品种有心脉隆注射液、安宫牛黄丸、人参再造丸、六味地黄丸、六灵丸、藿香正气水、感冒疏风片、清肺抑火片等。年生产规模为2000多吨,主要剂型有注射剂、丸剂(大蜜丸、小蜜丸、水丸、水蜜丸)、片剂、颗粒剂、散剂、酒剂、酊剂、糖浆剂,国药准字批文 130个,87个品种,137个品规,均是中药、天然药物。其中,国家二类新药“心脉隆注射液”由企业与大理学院联合研制,于2007年获准生产上市,为腾药的发展注入了新的活力。

规划:发展为以心脉隆注射液为主,传统普药为辅,日化保健品为补的上市企业。

党建:公司党总支下设5个党支部,共有党员62名(其中女党员37名)。

文化:公司起源于药王宫(建于明代天启六年)——全国中医药文化宣传教育基地,整个以求健康、传健康、学健康、食健康为主。公司秉承诚信制药,争做百年腾药。公司核心使命:“为人类健康创造卓越价值”,核心价值:“顾客第一服务他人 诚信 创新”。

诚信:公司一直秉承诚信制药的优良传承,用“宁为上药三分利,莫负良医九折肱”的对联警醒着一代又一代制药人。

创新:以心脉隆注射液为主的科研课题研究、美蠊系列日化保健品开发。


Yunnan tengyao Pharmaceutical Co., Ltd. (hereinafter referred to as "tengyao") was founded in 1956, changed into a joint-stock cooperative enterprise in 1997, completed the joint-stock transformation in September 2011 with the care and support of the county Party committee and government, and achieved strategic cooperation with Beijing Zhongzheng Wanrong pharmaceutical investment group in November of the same year. After more than 50 years of historical accumulation, tengyao has more than 600 employees (including sales staff) on the job at present, with a strong pharmaceutical technology foundation, and the company has a professional testing method based on continuous learning of modern science and technology. The organic combination of the two makes the "tengyao" products have excellent quality. The varieties created are Xinmailong injection, Angongniuhuang pill, Renshen Zaizai pill, Liuwei Dihuang pill, Liuling pill, Huoxiang Zhengqi water, Ganmao Shufeng tablet, Qingfei Yihuo tablet, etc. The annual production scale is more than 2000 tons, and the main dosage forms are injection, pill (big honey pill, small honey pill, water pill, water honey pill), tablet, granule, powder, liquor, tincture, syrup. There are 130 national drug approval documents, 87 varieties, 137 product specifications, all of which are traditional Chinese medicine and natural medicine. Among them, Xinmailong injection, a national second-class new drug, was jointly developed by the enterprise and Dali University, and was approved for production and listing in 2007, which injected new vitality into the development of tengyao. Planning: to develop into a listed enterprise mainly with Xinmailong injection, supplemented by traditional general medicine and supplemented by daily chemical health products. Party Construction: the company has 5 party branches under the general Party branch, with 62 party members (including 37 female party members). Culture: the company originated in the palace of Medicine (built in the sixth year of Tianqi in Ming Dynasty) - the national base of traditional Chinese medicine culture publicity and education, focusing on health, transmission, learning and eating. The company adheres to the integrity of pharmaceutical, striving to be a century drug. The company's core mission: "to create outstanding value for human health", and its core value: "customer first, serve others and innovate with integrity". Integrity: the company has always been adhering to the good heritage of integrity pharmaceutical, with the couplet of "better for the third profit of the drug, better for the nine fold arm" to alert generations of pharmaceutical people. Innovation: Research on Xinmailong injection as the main scientific research topic, and development of Periplaneta americana series of daily chemical health products.

本文链接: https://brand.waitui.com/19813d252.html 联系电话:08755133464

7×24h 快讯

RoboSense与上汽集团进入规模化量产合作新阶段

36氪获悉,RoboSense速腾聚创正式公布与上汽集团旗下汽车品牌飞凡汽车的定点合作。日前,双方合作的车型之一飞凡F7正式上市交付。这标志着,RoboSense速腾聚创与上汽集团的量产车型定点合作全面进入了规模化量产的新阶段。

44分钟前

热门中概股美股盘前多数上涨,京东涨超5%

36氪获悉,热门中概股美股盘前多数上涨,截至发稿,京东涨超5%,拟分拆京东产发、京东工业于香港联交所主板独立上市;微博涨超3%,拼多多、蔚来、小鹏汽车、爱奇艺涨超1%,B站涨0.49%,理想汽车涨0.24%,百度跌超2%。

44分钟前

贵州茅台:2022年净利润627.16亿元,同比增长19.55%

36氪获悉,贵州茅台发布年报,2022年营业收入1240.99亿元,同比增长16.87%;净利润627.16亿元,同比增长19.55%;基本每股收益49.93元。拟10派259.11元。

44分钟前

天齐锂业:2022年净利润241.25亿元,同比增长1060.47%

36氪获悉,天齐锂业发布年报,2022年营业收入404.48亿元,同比增长427.82%;净利润241.24亿元,同比增长1060.47%,拟10派30元。

44分钟前

亚朵集团上市后首份成绩单:2022年调整后净利润同比增85.6%至2.59亿元

亚朵集团发布2022年第四季度及全年业绩报告。2022年,亚朵集团实现营收22.63亿元,同比增长5.4%;调整后净利润(非公认会计准则)为2.59亿元,同比增长85.6%。截至2022年12月31日,亚朵集团现金及现金等价物为15.89亿元。报告期内,亚朵新开店191家,仅4家关店,在营酒店数量达932家,房间数达10.8万间,均较上年增长25%;场景零售业务增长迅猛,GMV同比增长42%至3.24亿元。

44分钟前

本页详细列出关于腾药Tengyao的品牌信息,含品牌所属公司介绍,腾药Tengyao所处行业的品牌地位及优势。
咨询